GH55
/ Genhouse Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 15, 2024
A Phase I/II Clinical Study to Evaluate The Safety, PK, PD of GH55 in Patients With MAPK Mutant Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=110 | Recruiting | Sponsor: Suzhou Genhouse Bio Co., Ltd.
Metastases • New P1/2 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1